Chemomab Therapeutics (ADR) (CMMB)
Develops nebokitug, a CCL24-neutralizing antibody for fibro-inflammatory diseases.
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Planned merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in RA continues to advance with closing expected by year-end
Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript
Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
Chemomab and Scipher announced a merger agreement to advance nebokitug into a Phase 2 precision medicine trial for the treatment of rheumatoid arthritis.
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC Patients with Co-Existing IBD— —Company Continues to Advance Multiple Partnering Options for Nebokitug— TEL AVIV, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2026, and provided a corporate update.
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance along with preparations to launch the PSC Phase 3 trial.
Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Significant Growth in Short Interest
Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ: CMMB - Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 18,047 shares, a growth of 100.7% from the December 15th total of 8,994 shares. Approximately 0.3% of the company's shares are short sold. Based
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a P hase 3 Registration Trial — TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the results of its Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis (PSC) were published in the current issue of the American Journal of Gastroenterology.1 The study showed that nebokitug was generally safe and well tolerated in patients with PSC for up to 48 weeks of treatment.
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinical Event Composite Endpoint — —Phase 2 SPRING Trial OLE Data Showing Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks Presented at AASLD 2025 — — New Clinical Data Presented at AASLD 2025 Provides Insights on Nebokitug's Direct Macrophage-Mediated Mechanisms that Are Relevant to Halting or Slowing PSC Disease Progression— —Multiple Partnering Options for Supporting the Nebokitug Phase 3 Program Continue to Advance— —Cash Runway Expected through End of Fourth Quarter of 2026— TEL AVIV, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the third quarter ended September 30, 2025, and provided a corporate update.
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
Chemomab announced three presentations "of distinction" at AASLD The Liver Meeting® 2025 featuring clinical data from the nebokitug Phase 2 trial in PSC.
Best Momentum Stocks to Buy for Oct. 23
PARR, CMMB and GES made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 23, 2025.
CMMB, with P&G Support, Responds to Deadly Cholera and Hunger Crisis in South Sudan
Juba, South Sudan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) is launching an emergency response in South Sudan as compounding crises threaten thousands of lives in Upper Nile region and Central Equatoria State. The devastating cholera outbreak has already infected more than 85,700 people as of August 5—many of them children under 14—with case fatality rates at times exceeding World Health Organization (WHO) emergency thresholds. Meanwhile, a hunger crisis deepens across most of the country.
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
— Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug's Unique Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in PSC Featured at Multiple Major Scientific Meetings— —FDA and Chemomab Align on CMC and Non-Clinical Toxicology Regulatory Path Forward for Nebokitug—` —Cash Runway through End of Second Quarter of 2026— —Announces Plans to Implement ADS Ratio Change Adjustment— TEL AVIV, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the second quarter ended June 30, 2025, and provided a corporate update.
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25
SPRING Trial Data Presented at BSG Live'25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 Treatment with Nebokitug Is Well-Tolerated and Associated with Substantial Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of PSC Disease Progression TEL AVIV, Israel and GLASGOW, United Kingdom, June 30, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that data from the company's Phase 2 SPRING trial of nebokitug (CM-101) in patients with primary sclerosing cholangitis (PSC) was presented in an oral session1 at BSG Live'25, the annual scientific meeting of the British Society for Gastroenterology, in Glasgow, UK.
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential Strategic Partners Continue— TEL AVIV, Israel, June 11, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported that it has obtained confirmation from the FDA on two significant development milestones as the company continues to finalize the nebokitug Phase 3 program.
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
—New Patent s Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Coverage Up T o 2041 — —Further Ex pands Protections Provided by Nebokitug 's Composition of Matter and Methods and Use Patents Issued in the U.S., Europe, Japan and A dditional Key Territories— TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that its lead product nebokitug (formerly CM-101) has been awarded new patent protections in China and Russia.
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
— Reported Positive 48-Week Data from SPRING Trial — Nebokitug Treatment in PSC P atients with M oderate/ A dvanced D isease R esulted in C ontinued I mprovements across K ey B iomarkers of Li ver I njury, I nflammation and Fi brosis — — Align ed with FDA on Pathway to Potential Regulatory Approval for the Treatment of PSC with a Single, Clinical-Events-Driven Clinical Trial— — Th e se Major Milestones Support the Advancement of Nebokitug to Phase 3 and Position It to Potentially Become the First FDA-Approved Treatment for PSC — — Cash Runway E xtended to the S econd Quarter of 2026 — — Company Advancing Multiple Partnering Options for Executing the Nebokitug Program — TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd.(Nasdaq:CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2025, and provided a corporate update.
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
SPRING Trial Data Presented at Digestive Disease Week® 2025 Shows that Nebokitug at 15 and 48 Weeks of Treatment Is Well-Tolerated and Associated with Significant Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of Disease Progression Confirms the Clinical Potential of Nebokitug As a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 TEL AVIV, Israel and SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that data from the company's Phase 2 SPRING trial of nebokitug (CM-101) in primary sclerosing cholangitis (PSC)1 was presented in an oral Distinguished Abstract Plenary session at Digestive Disease Week® (DDW 2025) in San Diego, California.
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases
Chemomab reported new clinical data to be presented at EASL 2025 that further confirms the potential of nebokitug as a first-in-class treatment for PSC.
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
TEL AVIV, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that clinical data on nebokitug (CM-101) for the treatment of patients with primary sclerosing cholangitis (PSC) will be presented at major upcoming scientific conferences including DDW25, Digestive Disease Week 2025®; EASL 2025, the Annual Congress of the European Association for the Study of the Liver; and BSG LIVE'25, the British Society of Gastroenterology's annual meeting.
Chemomab Announces New Medical and Clinical Appointments
David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience Jack Lawler, Who Oversaw the Conduct of Chemomab's Successful Phase 2 SPRING Trial in PSC, Assumes Chief Development Officer Role TEL AVIV, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that David M.